Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Anti-VEGF injections and macular atrophy progression in patients with neovascular age-related macular degeneration in remission

British Journal of Ophthalmology(2025)10.1136/bjo-2024-326124Source: DataRank Database

Anti-VEGF injections and macular atrophy progression in patients with neovascular age-related macular degeneration in remission is a research paper published in British Journal of Ophthalmology (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 1.94)OA: greenTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Ines D. Nagel ORCID,Akshay Agnihotri ORCID,Fritz Gerald P. Kalaw ORCID,Anna Heinke ORCID,Lingyun Cheng ORCID

Live enrichment

PubMed:40379450 PMC:PMC13001793 OpenAlex:https://openalex.org/W4410482388

UCSD Jacobs Retina Center

Grant: Unrestricted

NIH

Grant: 5R01EY033847

NIH

Grant: R01EY016323

National Institutes of Health

Grant: Bridge2AI

National Institutes of Health

Grant: OT2OD032644

UCSD Vision Research Center Core Grant

Grant: P30EY022589

NEI NIH HHS

Grant: R01 EY033847

NEI NIH HHS

Grant: R01 EY035262

FWCI

1.94

Citation Percentile

0.8%

Citation Trend

2026

green

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC13001793/

publisherhttps://syndication.highwire.org/content/doi/10.1136/bjo-2024-326124

journalhttps://doi.org/10.1136/bjo-2024-326124

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40379450

Fields of Study

Retinal Diseases and TreatmentsOphthalmology and Visual Impairment StudiesOcular Diseases and Behçet’s SyndromeHumansRetrospective StudiesFemaleMaleAngiogenesis InhibitorsDisease ProgressionAgedVascular Endothelial Growth Factor AIntravitreal InjectionsTomography, Optical CoherenceWet Macular DegenerationRanibizumabAged, 80 and overVisual AcuityFluorescein AngiographyBevacizumabMacula LuteaRemission InductionFollow-Up StudiesMiddle AgedAtrophy

MeSH Terms

BevacizumabRanibizumabAgedAged, 80 and overAtrophyFemaleFluorescein AngiographyFollow-Up StudiesHumansMacula LuteaMaleMiddle AgedRemission InductionRetrospective StudiesVisual AcuityDisease ProgressionAngiogenesis InhibitorsTomography, Optical CoherenceVascular Endothelial Growth Factor AWet Macular DegenerationIntravitreal Injections

Keywords

MedicineMacular degenerationRanibizumabOphthalmologyAtrophySurgeryRetrospective cohort studyBevacizumabInternal medicineChemotherapyRetinaAge-related macular degeneration

Sustainable Development Goals

SDG 0: Good health and well-being